Abstract
Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.
Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds
Current Drug Therapy
Title: New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Volume: 3 Issue: 1
Author(s): Carlos Alberto Manssour Fraga and Eliezer J. Barreiro
Affiliation:
Keywords: Symbiotic drugs, molecular hybridization, multifactorial diseases, therapeutic innovation, drug design, dual compounds
Abstract: Some physiopathological processes involved in the genesis of diseases could suggest the necessity of designing bioligands or prototypes that aggregate, in only one molecule, dual pharmacodynamical properties, becoming able to be recognized by two elected bioreceptors. This approach can have distinct aspects and, when a novel ligand or a prototype acts in two elected targets belonging to the same biochemical pathway, e.g. arachidonic acid cascade, it receives the denomination of dual or mix agent. On the other hand, if these two targets belong to distinct biochemical routes and both are related to the same disease, we can characterize the agents able to modulate it as symbiotic ligands or prototypes. In the present work, we provide some examples and applications of the molecular hybridization concept for the structural design of new symbiotic ligands and prototypes, especially those applied in the treatment of chronic-degenerative disorders.
Export Options
About this article
Cite this article as:
Manssour Fraga Alberto Carlos and Barreiro J. Eliezer, New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs, Current Drug Therapy 2008; 3 (1) . https://dx.doi.org/10.2174/157488508783331225
DOI https://dx.doi.org/10.2174/157488508783331225 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serum Cystatin C-A Useful Endogenous Marker of Renal Function in Intensive Care Unit Patients at Risk for or with Acute Renal Failure?
Current Medicinal Chemistry Prodrug Design Targeting Intestinal PepT1 for Improved Oral Absorption: Design and Performance
Current Drug Metabolism Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Calcium Channel Subtypes and Exocytosis in Chromaffin Cells at Early Life
Current Molecular Pharmacology The Use of Biomarkers in Sepsis: A Systematic Review
Current Pharmaceutical Biotechnology Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?
Current Pharmaceutical Design The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research Perioperative Management of Hyperlipidemia Medications
Current Clinical Pharmacology Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease
Current Vascular Pharmacology The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Effect of Piperine, Quercetin, Polysorbate 80 on the Oral Bioavailability of Losartan in Male Wistar Rats
Pharmaceutical Nanotechnology Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews